Germ-line mutations of the tumor suppressor APC are implicated in attenuated adenomatous polyposis coli (AAPC), a variant of familial adenomatous polyposis (FAP). AAPC is recognized by the occurrence of !100 colonic adenomas and a later onset of colorectal cancer (age 140 years). The aim of this study was to assess genotype-phenotype correlations in AAPC families. By protein-truncation test (PTT) assay, the entire coding region of the APC gene was screened in affected individuals from 11 AAPC kindreds, and their phenotypic differences were examined. Five novel germ-line APC mutations were identified in seven kindreds. Mutations were located in three different regions of the APC gene:
Introduction
Familial adenomatous polyposis (FAP) is an inherited, autosomal dominant syndrome caused by germ-line mutations of the adenomatous polyposis coli (APC) gene, APC (Groden et al. 1991; Kinzler et al. 1991) . Clinical diagnosis of FAP is usually based on the presence of 1100 colonic adenomas (Bussey 1975) , which, if left untreated, progress to colorectal cancer (CRC), typically at age X40 years (Gardner 1951) . Other features include variable age at onset of polyposis (age 10-40 years) and variable expressivity Giardiello et al. 1994) . Extracolonic manifestations in FAP include the occurrence of desmoids, congenital hypertrophic retinal pigment-epithelial lesions (CHRPE), upper-gastrointestinal (UGI) polyps, and cancers of the thyroid, brain, and hepatobiliary tract. In previous studies, association of colonic polyposis and CRC with osteomas, fibromas, or epidermoid cysts has been described as a distinct entity, "Gardner syndrome" (Gardner and Richards 1953) . That FAP and Gardner syndrome are the same genetic entity became apparent with the discovery of the APC gene and the identification of germ-line APC mutations in patients with those syndromes.
APC is a large (∼300 kD) multifunctional protein and consists of distinct sequence motifs that specify its interactions with diverse protein partners (Polakis 1997) . The majority of germ-line APC mutations cause truncated products and predominantly occur in the first half of the gene (Nagase et al. 1992a ). Some phenotypic variants of FAP have been specifically associated with distinct mutation patterns in the APC gene. Thus, the occurrence of CHRPE is correlated with APC mutations in the region spanning exons 9-15 (Olschwang et al. 1993b) , and the desmoid tumors are correlated with mutations in the region spanning codons 1444-1578 (Caspari et al. 1995) . With regard to colonic adenomatous polyposis, a "sparse" phenotype (1,000-2,000 polyps) has been correlated with germ-line APC mutations in the region spanning codons 213-1597 (Nagase et al. 1992a ); whereas a "profuse" (15,000 polyps) phenotype has been demonstrated to segregate with APC mutations in the region spanning codons 1250-1464 (Nagase et al. 1992b; Caspari et al. 1994; Gayther et al. 1994) .
Recognition of such genotype-phenotype associations, along with the identification of distinct structural motifs, has provided important insights into APC's function. For example, APC carries a series of b-catenin-binding sites in the region associated with profuse polyposis. Using these sites, APC regulates intracellular turnover of bcatenin (Su et al. 1993 ), a protein involved in cellular adhesion, communication, and cell signaling pathways that affect apoptosis and cell growth (Hü lsken et al. 1994; Morin et al. 1996 Morin et al. , 1997 Peifer 1996; Rubinfeld et al. 1996; Korinek et al. 1997) . Thus, mutant APC transcripts with deletions of the b-catenin-binding region function by mediating an imbalance of cell division over cell death, which likely results in an aggressive polyposis phenotype. Another functional domain, localized to the first 55 residues of APC, is involved in the protein-dimerization process . Mutation analyses have shown this domain to be almost always retained in the truncated mutant APC transcripts, which suggests that the dimerization domain is critical to APC's function.
Attenuated APC (AAPC) is a variant of FAP (Leppert et al. 1990 ) and also has been described as "hereditary flat adenoma syndrome" (Lynch et al. 1988 (Lynch et al. , 1995 . AAPC differs phenotypically from classical FAP, in the number of colonic adenomas (usually !100) that tend to be located proximal to the splenic flexure Giardiello et al. 1997; Gardner et al. 1997) . These adenomas may present with a flat (rather than polypoid) morphology. Gastric fundic polyps and duodenal adenomas are also seen, and, in contrast to what is seen in FAP, CHRPE lesions and desmoid tumors rarely have been described in AAPC (Lynch et al. 1995; Scott et al. 1995) . The average age at onset of CRC is later in AAPC (average age 55 years) than in classical FAP (average age 39 years) (Lynch et al. 1995) . Furthermore, some AAPC families may phenotypically overlap with the hereditary nonpolyposis CRC syndrome (HNPCC), in which adenomas also are located on the right side of the colon (Jass et al. 1994) . Alternatively, in some small nuclear AAPC families, the lack of accurate documentation regarding the number and/or the location of polyps may lead to a misdiagnosis of sporadic CRC.
In 1992, the attenuated variant was localized to the APC gene locus by molecular-genetic linkage analysis (Spirio et al. 1992 ). These observations were subsequently confirmed by the identification of four distinct germ-line mutations occurring at the 5 end of the APC gene (Spirio et al. 1993 ). Several reports have described AAPC families with unique APC mutations (Cama et al. 1994; Dobbie et al. 1994; Smith-Ravin et al. 1994; Varesco et al. 1994; van der Luijt et al. 1995; Giardiello et al. 1997) ; however, only a few studies have investigated genotype-phenotype associations in AAPC (Spirio et al. 1993; Giardiello et al. 1997) . In the present study, we used molecular-genetic characterization of APC to better classify kindreds that have a familial predisposition to colonic adenomas and CRC and that have phenotypic features not typical of FAP or HNPCC.
Subjects and Methods

Selection of Patients
Eleven unrelated kindreds with hereditary predisposition to colonic adenomas and CRC were identified, from the Familial Gastrointestinal Cancer Registry located at our institution. Most affected individuals had 110 but !100 adenomas, and 9 of 11 families had a history of CRC. Endoscopic, operative, and histopathological data were collected retrospectively. Complete follow-up information was obtained as well. Predictive genetic testing was offered to affected individuals, with pre-and posttest counseling (Soravia et al. 1997a ). Patient accrual, sample collection, and genetic screening were performed according to guidelines of the Human Ethics Committee of the University of Toronto.
Molecular-Genetic Analysis
The protein-truncation test (PTT) assay was used to screen for APC germ-line mutations (Powell et al. 1993; van der Luijt et al. 1994 ). Blood samples were obtained from affected individuals, and lymphoblastoid EpsteinBarr virus-transformed cell lines were established for some of these patients. RNA and DNA extraction was performed by use of TRIzolJ and DNAzolJ, according to the manufacturer's protocol (Life Technologies). Reverse-transcription PCR was performed by use of standard techniques. In brief, cDNA was generated from total RNA (2-5 mg) by use of random hexamers, 1 # first-strand buffer, 0.5 mM of deoxynucleotide triphosphate, 10 mM DTT, and 200 units of Superscript II reverse transcriptase (Bethesda Research Laboratories). cDNA and genomic DNA were amplified under the following conditions: initial denaturation at 95ЊC for 2 min; 35-40 cycles, each consisting of denaturation at 95ЊC for 30 s, annealing at 63ЊC-65ЊC for 1 min 30 s, and extension at 70ЊC for 2 min; and a final extension at 70ЊC for 5 min. Five-microliter aliquots of PCR products were electrophoresed on a 1.5% agarose gel, in order to confirm amplification.
The in vitro-synthesized PTT assay was performed by use of a commercial kit (TNT7 T7 Quick Coupled Transcription/Translation System; Promega), according to the manufacturer's protocol. In brief, APC exon 15 was amplified in four overlapping segments, as described elsewhere (Powell et al. 1993) . Exons 1-14 were amplified in two overlapping segments: 1A (exons 1-9) and 1B (exons 8-14). The 5 end of each forward primer had a T7 promoter sequence and a translation-initiation site for coupled in vitro transcription and translation. PCR products were separated on 12.5% polyacrylamide gels. Positive PTT results were confirmed by two independent PCR reactions.
For sequence determination, PCR products of the putative positive-PTT samples were electrophoresed on a 1.5% agarose gel for 45-60 min at 100 V and were stained with ethidium bromide. The band of interest was excised with a sterile scalpel blade, and DNA was extracted by use of the QIAquick Gel Extraction Kit (QIA-GEN). The dideoxy-mediated chain-termination method was used for DNA sequencing (Sanger et al. 1977) . For this purpose, we used a[ 33 P] dideoxynucleotide and a ThermoSequenase radiolabeled terminator sequencing kit (Amersham Life Science); sequencing was performed according to the manufacturer's protocol. Finally, the gel was autoradiographed by use of BioMax MR film (Kodak) for 24-48 h at room temperature. Additional confirmation was obtained by genomic DNA sequencing. Primers used for PTT-PCR and sequencing reactions are available on request.
Results
In 7 of the 11 kindreds, putative truncating mutations were identified as novel transcripts, by PTT analysis. Sequence characterization revealed five germ-line APC mutations in these seven families (table 1). To the best of our knowledge, all five APC mutations are novel (Bé-roud and Soussi 1996; De Vries et al. 1996) . In three AAPC kindreds, a truncated-protein product of ∼16 kD was identified, in addition to the wild-type protein for APC segments 1 (codons 1-811; fig. 1A , lanes 3 and 4) and 1A (codons 1-379; figs. 1A, lanes 1 and 2, and 1B, lanes 5-7). Sequence analysis revealed this truncation to be caused by exon 4 deletion, leading to a frameshift mutation and resulting in a stop codon (TGA) at nucleotide 551 (codon 184). In kindred 4, the size of the novel PTT product was ∼20 kD (fig. 1B, lane 5). DNA sequence analysis revealed a CrT transversion at nucleotide 487 (exon 4, codon 163), resulting in a substitution of glycine by a stop codon (CAGrTAG). In kindreds 5 and 6, the truncated proteins showed a similar pattern (doublet), ∼46 kD in size ( fig. 2A) . Subsequent characterization by sequencing identified two distinct APC germ-line mutations within exon 9. Specifically, in kindred 5, the mutation occurred at nucleotide 988 (deletion A), resulting in a frameshift leading to a stop codon (TAG) at nucleotide 1014, and, in kindred 6, a CrT transversion at nucleotide 994 resulted in a substitution of arginine by a stop (GCArTGA) at codon 332. Finally, in kindred 7, the size of the truncated protein was ∼48 kD ( fig. 2B ). By sequence analysis, the mutation was identified to be a 1-bp frameshift deletion (C) at APC nucleotide 6138 (codon 2047), leading to a stop codon (TGA) at nucleotide 6218.
Tables 2-4 summarize phenotypic and clinical data on the seven kindreds, according to the location of the APC mutations. Kindred 2 is a large AAPC family and spans four generations with 27 affected individuals. In this family, a variability was observed with respect to the number of colorectal adenomas (mean 142, range 2-580). A predominance of right-sided colonic polyps with rectal sparing was observed in all AAPC families. In kindreds with 5 -end APC mutations (table 2), the mean age at polyposis diagnosis was 42 years (range 39.5-45.2 years), with a mean of 96 polyps (range 1-580), and the mean age at CRC diagnosis was 58.1 years (range 29-76). In the group with mutations in APC exon 9, although both the mean age at polyposis diagnosis (39.7 years [range 12-64]) and the mean age at CRC diagnosis (54.2 years [range 42-67]) were comparable to those in the first group, the average number of polyps (22 [range 1-150]) was less (table 3). In the AAPC kindred with 3 -end APC mutations, mean age at polyposis diagnosis was 49 years (range 41-65), and mean number of colonic polyps was 14 (range 1-36); thus far, no CRC has been diagnosed in this family (table 4) .
Discussion
In this study, we have shown that AAPC is caused by mutations in three distinct regions of the APC gene-that is, at the 5 end, in the region spanning exons 4 and 5; in exon 9; and at the extreme 3 end. Phenotypic expression in these three groups of kindreds is variable but is definitely milder than that in classical FAP, indicating modified clinical-management protocols for affected AAPC patients and their at-risk relatives. Our data demonstrate that AAPC families carrying 5 germline APC mutations exhibit greater variability with regard to the frequency and age at onset of polyposis, such that the phenotypes of some affected patients are quite similar to that of classical FAP. Furthermore, duodenal adenomas occur with an increased severity in these families.
We have identified four AAPC kindreds with APC mutations located proximal to codon 168. Of these four kindreds, three carry the same APC mutation, and the fourth carries a truncating mutation within APC exon 4. To date, 13 AAPC families with germ-line APC mutations proximal to codon 168 have been described (Spirio et al. 1993; Olschwang et al. 1993a; Giardiello et al. 1997) . 5 APC mutations predict the synthesis of proteins shorter than those predicted from the APC mutations commonly associated with classical FAP (Horii et al. 1993; Samowitz et al. 1995) . Therefore, different properties of the two types of mutant APC proteins may be expected . Short APC peptides may be unable to compete with other peptide complexes, because of a lack of essential sequence motifs required for such protein-protein interaction. Alternatively, such alleles are likely to be unstable and may result in null alleles.
Two AAPC kindreds carry APC mutations in exon 9. This exon is usually alternatively spliced. Germ-line mutations in APC exons 6 and 9A, including those causing a splice-site defect, have been reported in AAPC families (Cama et al. 1994; Smith-Ravin et al. 1994; Varesco et al. 1994; van der Luijt et al. 1995) . Mutations occurring in alternatively spliced regions of APC would support the haploinsufficiency model, in which an unstable truncated mutant protein with a reduced amount of normal APC induces a less severe phenotype Yang et al. 1997) . Furthermore, the splicesite mutations of such APC exons are thought to provoke inefficient exon skipping, which may be responsible for the delay in the development of colonic polyposis (Varesco et al. 1994) . In the present study, although the mutations in exon 9 were located outside the alternatively spliced region, the phenotypes of these two kindreds are typical of AAPC (table 3) . Average age at diagnosis of polyposis is 40 years, and usually there are !100 right-sided colonic adenomas, with rectal-polyp sparing; gastric/duodenal manifestations were not observed in these families.
We found one kindred with a germ-line APC mutation at codon 2047, which appears to be one of the most 3 mutations reported in AAPC. In this kindred, the colonic phenotype is very mild, with !40 polyps, no CRC, and rectal-polyp sparing (table 4) . Previous studies have shown that germ-line mutations at the distal 3 end of APC correlate with the AAPC phenotype (Scott et al. 1995; Friedl et al. 1996; van der Luijt et al. 1996; Gardner et al. 1997) . Such mutant APC transcripts are likely to be proficient in b-catenin binding, thereby mediating signals that are important for cell adhesion and turnover (Friedl et al. 1996) . Alternatively, 3 -mutant APC proteins are likely to form stable homodimers and to retain partial function, as in the case of "leaky" mutant alleles (Spirio et al. 1993) . Kindreds with desmoid tumors but with almost no colonic manifestations have been reported recently (Eccles et al. 1996; Scott et al. 1996) . These families are noteworthy for having APC mutations in the 3 region of the gene. This variant of FAP has been termed "hereditary desmoid disease" and previously had been classified as "familial infiltrative fibromatosis" (MIM 135290). In these kindreds, CRC oc- Caspari et al. 1995) . In our AAPC kindreds, desmoid tumors have not been identified. A germ-line APC mutation was not identified in 4 of 11 kindreds. There are a number of possible explanations: the PTT assay may be unable to detect all mutations in these genes; the mutations may be located in a gene region (e.g., intronic or promoter regions) that was not investigated, or a mutation in a gene(s) other than APC may be the underlying defect in these families.
Two phenotypic features of our AAPC families are worth emphasizing: (1) we observed rectal-polyp sparing in patients who underwent total colectomy and ileorectal anastomosis, after a mean follow-up period of 11.7 years (range 1-26 years); and (2) we also observed an increased trend toward development of gastric and duodenal adenomas, with the occurrence of duodenal cancer in one case, as reported elsewhere (Soravia et al. 1997b; Zwick et al. 1997) . Clinical review of AAPC families with 5 -end APC mutations (table 2) demonstrates that, although the number of colorectal adenomas usually is !100, in some cases variability is observed with regard to the number of colonic polyps (i.e., there are 1100), with a predominance of polyps located on the right side, as has been described elsewhere (Burt et al. 1995) . In families described here, the average age at CRC diagnosis is ∼58 years, whereas the average age at polyposis diagnosis is 42 years; these observations are in agreement with other reports (Dobbie et al. 1994; Lynch et al. 1995; Giardiello et al. 1997) .
Differences in the APC mutation sites alone cannot completely account for intra-and interfamilial variation in the polyposis phenotypes in these families. Another likely explanation for phenotypic variability is the presence of a modifier gene(s) that may influence the phenotypic expression of the APC gene. Such a gene is probably comparatively polymorphic, since phenotypic variability occurs both within and between families. For example, a modifier gene located on chromosome 1p35-36 may influence the severity of duodenal polyposis in FAP (Tomlinson et al. 1996; Dobbie et al. 1997) . It is also likely that environmental factors, such as diet, play an important role in AAPC, as has been demonstrated in the mouse models of FAP (Hioki et al. 1997) .
The use of molecular-genetic testing has been suggested as an aid in decision making with respect to the type of surgical procedure (total colectomy vs. restorative proctocolectomy) based on the risk of rectal cancer in FAP . This suggestion has been challenged by others (Gareth et al. 1997) , because few relevant clinical data had been given to support it. The lifetime risk for development of CRC has not yet been estimated in AAPC. Therefore, clinical decision making with respect to the type of surgical procedure should rely on a combination of factors, including age at AAPC diagnosis, number of adenomas (120), location of polyps (right-side colon), frequency of polyp recurrence, and polyp morphology (confluent vs. scattered polyps). A patient's compliance with the clinical-surveillance regimen should also be taken into account. Finally, this information needs to be correlated with the molecular diagnosis of AAPC in affected and/or presymptomatic individuals of such kindreds.
In view of our experience, the following information seems relevant for the clinical management of AAPC kindreds: (1) predictive genetic testing can be offered to presymptomatic relatives in AAPC families with a known germ-line mutation; (2) colonoscopy, as opposed to sigmoidoscopy, should be advised for endoscopic sur-veillance, because of the right-side location of colorectal adenomas; (3) UGI endoscopic surveillance is warranted in an attempt to detect premalignant gastric or duodenal tumors; and (4) individuals affected with AAPC may require total colectomy with ileo-rectal anastomosis only when prophylactic colectomy is advised. Finally, the rare occurrence of rectal polyps in AAPC is noteworthy; however, further clinical studies with longer follow-up are needed in order to prove that the risk of rectal cancer is lower in AAPC than in classical FAP (Nugent and Phillips 1992) .
